RSM18 Antibody

What is RAD18 and what cellular functions does it perform?

RAD18 functions as an E3 ubiquitin-protein ligase involved in postreplication repair of UV-damaged DNA. It plays a critical role in gap-filling of daughter strands during replication of damaged DNA. The protein associates with the E2 ubiquitin conjugating enzyme UBE2B to form the UBE2B-RAD18 ubiquitin ligase complex, which is involved in mono-ubiquitination of DNA-associated PCNA (Proliferating Cell Nuclear Antigen) on 'Lys-164'. RAD18 also possesses single-stranded DNA (ssDNA) binding activity, which is essential for its role in DNA damage response mechanisms . Understanding RAD18's cellular functions provides crucial context for researchers designing experiments to study DNA repair mechanisms and genomic stability.

What are the common alternative names for RAD18 in scientific literature?

In scientific literature and databases, RAD18 may be referenced under several alternative designations: RNF73, E3 ubiquitin-protein ligase RAD18, Postreplication repair protein RAD18, RING finger protein 73, RING-type E3 ubiquitin transferase RAD18, hHR18, and hRAD18 . Researchers should be aware of these nomenclature variations when conducting literature searches to ensure comprehensive coverage of relevant publications.

What is the specificity of commercially available RAD18 antibodies?

Commercial RAD18 antibodies, such as the rabbit polyclonal antibody ab188235, are typically raised against specific immunogens corresponding to defined regions of the protein. For instance, ab188235 is generated against a recombinant fragment protein within Human RAD18 amino acids 250 to C-terminus . This specificity information is crucial for researchers to evaluate whether an antibody will recognize their protein of interest, particularly when studying specific domains or post-translational modifications of RAD18.

What applications are RAD18 antibodies validated for in research settings?

RAD18 antibodies are validated for multiple research applications including:

• Immunoprecipitation (IP): For isolation of RAD18 protein complexes

• Western Blotting (WB): For detection and quantification of RAD18 protein

• Immunocytochemistry/Immunofluorescence (ICC/IF): For cellular localization studies

These applications have been confirmed to work with human and mouse samples . The suitability of an antibody for specific applications depends on rigorous validation, often demonstrated through peer-reviewed publications that have utilized the antibody successfully.

How can researchers validate the specificity of RAD18 antibodies in their experiments?

Validation of RAD18 antibody specificity should involve multiple approaches:

• Positive control: Use cell lines known to express RAD18 (e.g., U2OS cells)

• Negative control: Compare with RAD18 siRNA-treated samples where protein expression is knocked down

• Band size verification: Confirm detection of a band at the expected molecular weight for RAD18

• Species cross-reactivity assessment: Test antibody performance across relevant species based on sequence homology

Western blot validation of RAD18 antibody specificity can be demonstrated by comparing control lysates with siRNA-treated samples. For example, ab188235 shows detection of RAD18 in control U2OS cell lysate with significant reduction of signal in RAD18 siRNA-treated U2OS cells .

What are the optimal dilution factors for different experimental applications of RAD18 antibody?

Optimal working dilutions for RAD18 antibodies vary by application type:

These recommendations serve as starting points; researchers should optimize conditions for their specific experimental systems .

How can researchers use RAD18 antibodies to study DNA damage response pathways?

To study DNA damage response pathways using RAD18 antibodies, researchers can implement several advanced approaches:

• Time-course experiments: Monitor RAD18 recruitment to sites of DNA damage after UV irradiation or treatment with DNA-damaging agents.

• Co-localization studies: Use dual immunofluorescence with antibodies against other DNA repair proteins (e.g., PCNA, ubiquitin) to analyze complex formation.

• Chromatin immunoprecipitation (ChIP): Investigate RAD18 association with specific genomic regions after DNA damage.

• Proximity ligation assay (PLA): Detect direct protein-protein interactions between RAD18 and other repair factors in situ.

These methodologies provide mechanistic insights into how RAD18 functions within the broader context of DNA damage response networks.

What are the considerations for studying RAD18 post-translational modifications?

When investigating RAD18 post-translational modifications (PTMs), researchers should consider:

• Specific PTM-sensitive antibodies: Use antibodies that recognize RAD18 only when modified (e.g., phosphorylated, ubiquitinated).

• Phosphatase/deubiquitinase inhibitors: Include appropriate inhibitors in lysis buffers to preserve the PTM of interest.

• Enrichment strategies: Implement phosphopeptide enrichment or ubiquitin remnant motif immunoprecipitation before analysis.

• Mass spectrometry validation: Confirm PTM sites identified by antibody-based methods using mass spectrometry.

• Functional mutants: Compare wild-type RAD18 with point mutants where potential modification sites are altered.

Understanding these modifications is critical for deciphering RAD18 regulation in response to cellular stresses and DNA damage.

How can biophysics-informed modeling help in designing antibodies with specific binding profiles?

Biophysics-informed modeling approaches, as demonstrated in recent research, can help design antibodies with customized specificity profiles:

• Binding mode identification: Computational models can identify distinct binding modes associated with specific ligands, enabling the prediction of antibody variants with desired specificity.

• Training on experimental selections: Models trained on data from phage display experiments can predict outcomes for new ligand combinations and generate novel antibody sequences.

• Energy function optimization: By optimizing energy functions associated with different binding modes, researchers can design antibodies that are either cross-specific (interacting with several ligands) or highly specific (interacting with a single ligand while excluding others) .

This computational approach extends beyond what can be achieved through experimental selection alone, allowing researchers to design antibodies with tailored specificity profiles for challenging research applications.

How should researchers design validation experiments when working with new RAD18 antibodies?

When working with new RAD18 antibodies, a systematic validation approach should include:

• Western blot validation:

  • Compare detection in multiple cell lines with known RAD18 expression

  • Confirm specificity using RAD18 knockout or knockdown controls

  • Verify molecular weight and banding pattern

• Immunofluorescence validation:

  • Assess localization pattern (expected to be predominantly nuclear)

  • Evaluate changes in localization after DNA damage induction

  • Compare with alternative antibodies or tagged RAD18 constructs

• Functional validation:

  • Test antibody's ability to detect changes in RAD18 levels or localization after relevant stimuli

  • Confirm that the antibody doesn't interfere with RAD18's normal function in immunoprecipitation experiments

Documentation of these validation steps is essential for publication and reproducibility purposes.

What alternative methods exist for studying RAD18 when antibodies have limitations?

When antibodies present limitations, researchers can employ alternative approaches:

• Expression of tagged RAD18: Use epitope tags (FLAG, HA, GFP) for detection with well-validated tag antibodies.

• CRISPR-Cas9 knock-in: Generate endogenous tags at the RAD18 locus to maintain physiological expression levels.

• Proximity labeling approaches: BioID or APEX2 fusions to identify RAD18 interactors without requiring direct antibody recognition.

• Mass spectrometry-based proteomics: Targeted MS approaches to detect and quantify RAD18 peptides directly.

• RNA-based detection methods: Assess RAD18 mRNA expression using RT-qPCR or RNA-FISH as proxies for protein expression.

These approaches can complement or replace antibody-based methods when specificity or sensitivity issues arise.

What is the optimal methodology for using dried blood microsampling in antibody studies?

Recent research demonstrates that dried blood microsampling can be effectively used in antibody studies with the following methodological considerations:

• Collection method: Use Volumetric Absorptive Microsampling (VAMS) devices that collect precise blood volumes (e.g., 20 μL).

• Extraction protocol: Extract antibodies from dried blood using appropriate buffer systems (typically 200 μL buffer for a 20 μL VAMS device).

• Assay adaptation: Modify immunoassay protocols to account for the differences between serum and blood samples, including adjusting minimum required dilution (MRD).

• Data correlation: Establish correlation factors between serum and dried blood measurements, as antibody concentrations in blood are expected to be lower than in serum due to the cellular fraction.

• Validation criteria: Validate using multiple analysis types (e.g., pharmacokinetics, immunogenicity, and neutralization activity) .

This approach reduces patient burden and facilitates sample collection in resource-constrained settings, showing strong correlation (>90% agreement) with traditional serum measurements .

What are the common issues encountered when using RAD18 antibodies in Western blotting?

Researchers frequently encounter these challenges when using RAD18 antibodies in Western blotting:

• High background: May result from insufficient blocking or overly concentrated primary antibody.

  • Solution: Optimize blocking conditions (try 5% BSA instead of milk) and titrate antibody concentration.

• Multiple bands: Can indicate degradation products, isoforms, or non-specific binding.

  • Solution: Use freshly prepared lysates with protease inhibitors and validate with knockdown controls.

• Weak or no signal: May occur due to low expression levels or poor transfer efficiency.

  • Solution: Increase protein loading, optimize transfer conditions, or use enhanced chemiluminescence reagents.

• Variable results between experiments: Often relates to inconsistent sample preparation.

  • Solution: Standardize lysis conditions and handling of samples between experiments.

Systematic troubleshooting through these parameters can significantly improve reproducibility.

How can researchers distinguish between genuine RAD18 signal and artifacts?

To distinguish genuine RAD18 signal from artifacts, implement these analytical approaches:

• Use multiple antibodies: Compare results using antibodies targeting different RAD18 epitopes.

• Include appropriate controls:

  • Positive control: Overexpression of RAD18

  • Negative control: RAD18 knockdown/knockout

  • Peptide competition: Pre-incubation with immunizing peptide should abolish specific signals

• Expected molecular weight verification: RAD18 should appear at approximately 55-60 kDa.

• Functional validation: Confirm that signal changes predictably after DNA damage or other relevant stimuli.

• Cross-reference with orthogonal methods: Compare protein detection with mRNA expression or mass spectrometry data.

These approaches collectively provide strong evidence for signal authenticity and help eliminate false interpretations.

How should researchers analyze and interpret public antibody datasets for comparative studies?

When analyzing public antibody datasets for comparative studies, researchers should implement these methodological steps:

• Standardized data processing:

  • Normalize data across different studies using common reference points

  • Account for differences in experimental platforms and protocols

• Sequence analysis approach:

  • Analyze immunoglobulin V and D gene usages

  • Examine complementarity-determining region (CDR) sequences, particularly CDR H3

  • Assess patterns of somatic hypermutations

• Computational tools:

  • Apply deep-learning models trained on large antibody datasets

  • Use these models to distinguish between antibodies to different antigens

  • Implement clustering algorithms to identify public (common) antibody responses

• Validation strategies:

  • Cross-validate findings using independent datasets

  • Confirm computational predictions with experimental testing

This systematic approach has been successfully applied to analyze public antibody responses to various antigens, including SARS-CoV-2 spike protein, providing insights into common molecular features of antibody responses .

How might RAD18 antibodies contribute to understanding cancer development and treatment resistance?

RAD18 antibodies can provide critical insights into cancer biology through:

• Biomarker development: Evaluating RAD18 expression levels in tumor samples to predict treatment responses, particularly to DNA-damaging chemotherapeutics.

• Mechanism studies: Investigating how RAD18-mediated damage tolerance pathways contribute to genomic instability and mutagenesis during cancer evolution.

• Resistance mechanisms: Elucidating how upregulation of RAD18 might confer resistance to platinum compounds and other DNA-crosslinking agents by enabling cancer cells to bypass damage.

• Combination therapy strategies: Identifying potential synergistic effects between RAD18 inhibition and conventional DNA-damaging treatments through antibody-based mechanistic studies.

These applications could ultimately inform precision medicine approaches for cancer treatment based on RAD18 expression and activity profiles.

What emerging technologies might enhance the specificity and utility of antibodies in research?

Emerging technologies poised to transform antibody research include:

• Biophysics-informed computational design: Using machine learning models trained on experimental selection data to design antibodies with customized specificity profiles, allowing for precise target discrimination even among highly similar epitopes .

• Microfluidic antibody screening platforms: Enabling high-throughput screening of antibody specificity and affinity with minimal sample requirements.

• Cryo-EM and structural analysis: Providing atomic-resolution insights into antibody-antigen interactions to guide rational design of improved research reagents.

• Single-cell antibody repertoire analysis: Capturing the diversity of antibody responses at unprecedented resolution to inform better antibody design.

• Nanobody and alternative scaffold technologies: Developing smaller binding proteins with enhanced tissue penetration and stability for specialized research applications.

These technologies collectively promise to address current limitations in antibody specificity and performance in complex research applications.

How can dried blood microsampling advance longitudinal antibody studies in resource-limited settings?

Dried blood microsampling offers significant advantages for longitudinal antibody studies, particularly in resource-limited settings:

• Reduced infrastructure requirements: Eliminates need for centrifugation, cold chain, and specialized phlebotomy equipment.

• Simplified collection protocol: Enables collection by less specialized personnel or even self-collection by study participants.

• Enhanced stability: Antibodies in dried blood spots generally remain stable at ambient temperature for extended periods.

• Correlation with traditional methods: Studies demonstrate >90% agreement between dried blood and serum measurements for antibody concentration, antidrug antibodies, and viral neutralizing activity .

• Feasibility for pediatric studies: Particularly valuable for studies involving infants and children where minimizing blood volume is critical.

Implementation of this approach could significantly expand the scope and inclusivity of global clinical trials, especially for antibody-based therapeutics targeting infectious diseases prevalent in low- and middle-income countries .

What are the key considerations for researchers selecting RAD18 antibodies for their studies?

When selecting RAD18 antibodies, researchers should prioritize:

• Application-specific validation: Ensure the antibody has been validated for your specific application (WB, IP, ICC/IF) with published evidence.

• Species compatibility: Verify cross-reactivity with your experimental model system (human, mouse, etc.).

• Epitope location: Consider whether the epitope region is relevant to your research question (e.g., antibodies targeting functional domains vs. C-terminal regions).

• Batch consistency: Request information on lot-to-lot validation to ensure reproducibility across studies.

• Citation record: Review publications that have successfully used the antibody in similar experimental contexts.

• Protocol availability: Access to detailed protocols optimized for the specific antibody can significantly reduce troubleshooting time.